HAN

October 17, 2012, 13:15 (1:15 PM ET)CDCHAN-00329-2012-10-17-UPD-NThe Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) continue to work closely with state public health departments on a multistate investigation of fungal meningitis and joint infections among patients who received a methylprednisolone acetate injection prepared by the New England Compounding Center (NECC) in Framingham, Mass. Some of these patients who received epidural injections also suffered strokes that may have resulted from their infection. This HAN notice provides updated information on the following:\u2022 Status of the investigation.\u2022 FDA issuance of a MedWatch Safety Alert on October 15 advising clinicians to follow-up with patients who received an injectable NECC product, including any ophthalmic drug that is injectable or used in conjunction with eye surgery, and a cardioplegic solution purchased from or produced by NECC after May 21, 2012.\u2022 Recommendations for clinicians.\u2022 Case definition.2012Multistate Meningitis Outbreak Investigation (October 2012)Fungal Anti-inflammatoryFungalAspergillus fumigatusMethylprednisolone acetateExserohilum rostratumCladosporiu